Friday, July 10, 2026

Drug profile · INN

carteolol hydrochloride

carteolol hydrochloride (CARTEOLOL HYDROCHLORIDE) is a adrenergic receptor beta antagonist. Route of administration: ophthalmic. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — carteolol hydrochloride
US status
approved
Class
Route
OPHTHALMIC
Patents
0
Programs
0
Data quality
0.84

Quick answer

carteolol hydrochloride (CARTEOLOL HYDROCHLORIDE) is a adrenergic receptor beta antagonist. Route of administration: ophthalmic. Current US regulatory status: approved.

Key facts

INN carteolol hydrochloride
Brand CARTEOLOL HYDROCHLORIDE
Mechanism Adrenergic receptor beta antagonist
Target Adrenergic receptor beta
Route OPHTHALMIC
Formulation SOLUTION/DROPS

Mechanism of action

Adrenergic receptor beta antagonist

Primary target: Adrenergic receptor beta

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. isoproterenol hydrochloride Adrenergic receptor beta agonist
  2. isoproterenol sulfate Adrenergic receptor beta agonist

Frequently asked questions

What is carteolol hydrochloride?

carteolol hydrochloride (CARTEOLOL HYDROCHLORIDE) is a adrenergic receptor beta antagonist. Route of administration: ophthalmic. Current US regulatory status: approved.

What is the brand name for carteolol hydrochloride?

CARTEOLOL HYDROCHLORIDE is a marketed brand name for carteolol hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of carteolol hydrochloride?

carteolol hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.